Skip to main content

Table 2 Baseline characteristics and treatment administered. Only patients with genotyping and PC1/2 results are presented

From: Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatmentsa WWARN individual patient data meta-analysis

 

Asia

Africa

N

Median (range) or N (%)

N

N (%) or median (range)

Age (years)

2630

21 [0.1–70]

204

4.7 [0.7–29]

 < 1 year

 

8 [0]

 

11 [5]

 1–4 years

 

185 [7]

 

98 [48]

 5–11 years

 

407 [15]

 

82 [40]

 12+ years

 

2030 [77]

 

13 [6]

Parasitemia (microliter)

2631

97,214 [455–2,409,008]

204

53,507 [2240 - 605,329]

Temperature (C)

1658

38.2 [34.1–41.5]

204

37.6 [34.7–40.8]

Hemoglobin (g/dL)

770

13.1 [2.1–19.3]

26

10.8 [6.3–14.2]

Hematocrit (%)

1542

40 [12–55]

140

31 [21–44]

Artemisinin derivative: total 3 days dose (mg/kg)

AL

0

 

80

9.3 [5.2–16.0]

AS

433

8.3 [1.0–49.7]

0

 

AS + ACT1

1638

8.3 [0.5–28.9]

83

11.8 [4.7–15]

ASAQ

0

 

41

13.0 [8.6–16.7]

ASMQ

81

8.0 [3.8–16.1]

0

 

DHAPIP

430

6.7 [3.0–17.8]

0

 
  1. 1Artesunate was given in the first 3 days alone, followed by ACT